June 12, 2020 / 11:14 AM / a month ago

BRIEF-Aptose Presents Early Phase 1A/B CG-806 Clinical Findings

June 12 (Reuters) - Aptose Biosciences Inc:

* APTOSE PRESENTS EARLY PHASE 1A/B CG-806 CLINICAL FINDINGS AT THE 25TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION

* APTOSE BIOSCIENCES - CG-806 WAS WELL-TOLERATED IN PATIENTS TREATED AT 150MG, 300MG AND 450MG BID OVER MULTIPLE CYCLES

* APTOSE BIOSCIENCES- NEW IND SUBMITTED TO BEGIN TESTING CG-806 IN AML PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below